Our top pick for
Theratechnologies Inc is a drug manufacturers-specialty & generic business based in the US. Theratechnologies shares (THTX) are listed on the NASDAQ and all prices are listed in US Dollars. Theratechnologies employs 54 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$3.50|
|52-week range||$1.83 - $4.25|
|50-day moving average||$3.65|
|200-day moving average||$3.61|
|Wall St. target price||$4.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.31|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-0.57%|
|1 month (2021-09-24)||-14.00%|
|3 months (2021-07-23)||3.5|
|6 months (2021-04-23)||2.04%|
|1 year (2020-10-23)||70.73%|
|2 years (2019-10-24)||-11.95%|
|3 years (2018-10-24)||5.5144|
|5 years (2016-10-24)||37.45%|
Valuing Theratechnologies stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Theratechnologies's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Theratechnologies's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.3 million.
The EBITDA is a measure of a Theratechnologies's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$70.2 million|
|Gross profit TTM||$44 million|
|Return on assets TTM||-11.64%|
|Return on equity TTM||-154.66%|
|Market capitalisation||$335.6 million|
TTM: trailing 12 months
There are currently 194,952 Theratechnologies shares held short by investors – that's known as Theratechnologies's "short interest". This figure is 24.8% up from 156,273 last month.
There are a few different ways that this level of interest in shorting Theratechnologies shares can be evaluated.
Theratechnologies's "short interest ratio" (SIR) is the quantity of Theratechnologies shares currently shorted divided by the average quantity of Theratechnologies shares traded daily (recently around 226688.37209302). Theratechnologies's SIR currently stands at 0.86. In other words for every 100,000 Theratechnologies shares traded daily on the market, roughly 860 shares are currently held short.
However Theratechnologies's short interest can also be evaluated against the total number of Theratechnologies shares, or, against the total number of tradable Theratechnologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Theratechnologies's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Theratechnologies shares in existence, roughly 0 shares are currently held short) or 0.0021% of the tradable shares (for every 100,000 tradable Theratechnologies shares, roughly 2 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Theratechnologies.
Find out more about how you can short Theratechnologies stock.
We're not expecting Theratechnologies to pay a dividend over the next 12 months.
Over the last 12 months, Theratechnologies's shares have ranged in value from as little as $1.83 up to $4.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Theratechnologies's is 1.749. This would suggest that Theratechnologies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Theratechnologies Inc. , a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.